Pseudomembranous colitis: Causes and cures

被引:55
作者
Surawicz, CM
McFarland, LV
机构
[1] Univ Washington, Harborview Med Ctr, Div Gastroenterol, Seattle, WA 98104 USA
[2] Biocodex Inc, Seattle, WA USA
关键词
Clostridium difficile; pseudomembranous colitis; antibiotic side effects;
D O I
10.1159/000007633
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Clostridium difficile is the most common nosocomial pathogen of the gastrointestinal tract and has increased in frequency over time. Typical symptoms of C. difficile infection include diarrhea, which is usually nonbloody, or colitis associated with severe abdominal pain, fever and/or gross or occult blood in the stools, Pseudomembranous colitis (PMC), the severest form of this disease, occurs as a result of a severe inflammatory response to the C. difficile toxins, Th is review focuses on PMC, as this severe form is associated with the greatest medical concern. Diagnosis rests on detection of C. difficile in the stool, either by culture, tissue culture assay for cytotoxin B or detection of antigens in the stool by rapid enzyme immunoassays. Oral therapy with metronidazole 250 mg 4 times a day for 10 days is the recommended first-line therapy. Vancomycin is also effective, but its use must be limited to decrease the development of vancomycin-resistant organisms such as enterococci. Vancomycin (125-500 mg 4 times a day for 10 days) should be limited to those who cannot tolerate or have not responded to metronidazole, or when metronidazole use is contraindicated, as in the first trimester of pregnancy. A therapeutic response within a few days is usual. Recurrence of symptoms after antibiotics occurs in 20% of cases and is associated with persistence of C. difficile in the stools, Further recurrences then become more likely. Therapy with antibiotics in a pulsed or tapered regimen is often effective as are efforts to normalize the fecal flora. The yeast Saccharomyces boulardii has been proven in controlled trials to reduce recurrences when given as an adjunct to antibiotic therapy. Careful hand washing and environmental decontamination are necessary to prevent epidemics.
引用
收藏
页码:91 / 100
页数:10
相关论文
共 89 条
[21]  
DIGNAN CR, 1997, AM J SURG PATHOL, V21, P700
[22]  
EDMOND MB, 1995, CLIN INFECT DIS, V20, P1134
[23]   SUPPRESSION BY SACCHAROMYCES-BOULARDII OF TOXIGENIC CLOSTRIDIUM-DIFFICILE OVERGROWTH AFTER VANCOMYCIN TREATMENT IN HAMSTERS [J].
ELMER, GW ;
MCFARLAND, LV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (01) :129-131
[24]   Biotherapeutic agents - A neglected modality for the treatment and prevention of selected intestinal and vaginal infections [J].
Elmer, GW ;
Surawicz, CM ;
McFarland, LV .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (11) :870-876
[25]   DIAGNOSIS AND TREATMENT OF CLOSTRIDIUM-DIFFICILE COLITIS [J].
FEKETY, R ;
SHAH, AB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (01) :71-75
[26]  
Fekety R, 1997, AM J GASTROENTEROL, V92, P739
[27]   TREATMENT OF ANTIBIOTIC-ASSOCIATED CLOSTRIDIUM-DIFFICILE COLITIS WITH ORAL VANCOMYCIN - COMPARISON OF 2 DOSAGE REGIMENS [J].
FEKETY, R ;
SILVA, J ;
KAUFFMAN, C ;
BUGGY, B ;
DEERY, HG .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (01) :15-19
[28]  
Finney JMT, 1983, B JOHNS HOPKINS HOSP, V45, P53
[29]   PSEUDOMEMBRANOUS COLITIS ASSOCIATED WITH SINGLE-DOSE CEPHALOSPORIN PROPHYLAXIS [J].
FREIMAN, JP ;
GRAHAM, DJ ;
GREEN, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (07) :902-902
[30]   CLINICAL AND ENDOSCOPIC FINDINGS IN PATIENTS EARLY IN THE COURSE OF CLOSTRIDIUM DIFFICILE ASSOCIATED PSEUDOMEMBRANOUS COLITIS [J].
GEBHARD, RL ;
GERDING, DN ;
OLSON, MM ;
PETERSON, LR ;
MCCLAIN, CJ ;
ANSEL, HJ ;
SHAW, MJ ;
SCHWARTZ, ML .
AMERICAN JOURNAL OF MEDICINE, 1985, 78 (01) :45-48